Harnessing RNA interference to develop neonatal therapies: From Nobel Prize winning discovery to proof of concept clinical trials

Early Human Development

Volumn 85, Issue 10 SUPPL., 2009, Pages

  DeVincenzo, John P ^a  

^a UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

Author keywords

Antiviral; Neonatal; Respiratory viruses; RNA biology; RNA interference; RNAi; SiRNA; Therapy

Indexed keywords

SMALL INTERFERING RNA;

ARTICLE; AWARDS AND PRIZES; BIOLOGICAL MODEL; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; DRUG DESIGN; GENETICS; HUMAN; NEWBORN; RARE DISEASE; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RESPIRATORY TRACT INFECTION; RNA INTERFERENCE; VIROLOGY; VIRUS INFECTION;

CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; INFANT, NEWBORN; MODELS, GENETIC; NOBEL PRIZE; RARE DISEASES; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY TRACT INFECTIONS; RNA INTERFERENCE; RNA, SMALL INTERFERING; VIRUS DISEASES;

EID: 76249117990     PISSN: 03783782     EISSN: 18726232     Source Type: Journal    
DOI: 10.1016/j.earlhumdev.2009.08.013     Document Type: Article

References (17)

1. Fire A., Xu S., Montgomery M.K., Kostas S.A., Driver S.E., Mello C.C. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998, 391:806-811.
2. Elbashir S.M., Harborth J., Lendeckel W., Yalcin A., Weber K., Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001, 411:494-498.
3. Alexopoulou L., Holt A.C., Medzhitov R., Flavell R.A. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 2001, 413:732-738.
4. Hornung V., Guenthner-Biller M., Bourquin C., et al. Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dentritic cells through TLR7. Nat Med 2005, 11:263-270.
5. Schlee M., Hornung V., Hartmann G. siRNA and isRNA: two edges of one sword. Molec Ther 2006, 14:463-469.
6. de Fougerolles A., Vornlocher H., Maraganore J., Lieberman J. Interfering with disease: a progress report on siRNA-based therapeutics. Nat Rev, Drug Dev 2007, 6:443-453.
7. Johnson J.E., Gonzales R.A., Olson S.J., Wright P.F., Graham B.S. The histopathology of fatal untreated human respiratory syncytial virus infection. Mod Pathol 2007, 20:108-119.
8. Zhang L., Peeples M.E., Boucher R.C., Collins P.L., Pickles R.J. Respiratory syncytial virus infection of human airway epithelial cells is polarized, specific to ciliated cells, and without obvious cytopathology. J Virol 2002, 76:5654-5666.
9. DeVincenzo J.P. Respiratory Syncytial Virus infections in hematopoietic stem cell transplant recipients and other severely immunocompromised patients. Pediatr Pathol Molec Med 2000, 19:115-132.
10. Zhang X., Shan P., Jiang D., et al. Small interfering RNA targeting heme oxygenase-1 enhances ischemia reperfusion induced lung apoptosis. J Biol Chem 2004, 279:10677-10684.
11. Bitko V., Musiyenko A., Shulyayeva O., Barik S. Inhibition of respiratory viruses by nasally administered siRNA. Nat Med 2005, 11:50-55.
12. Reassessment of the indications for ribavirin therapy in respiratory syncytial virus infections. Pediatrics 1996, 97:137-140. American Academy of Pediatrics CoID.
13. DeVincenzo J. Pre-emptive ribavirin for 'RSV' in BMT. Bone Marrow Transplant 2000, 26:113-114.
14. Kimpen J.L., Schaad U.B. Treatment of respiratory syncytial virus bronchiolitis: 1995 poll of members of the European Society for Paediatric Infectious Diseases. Pediatr Infect Dis J 1997, 16:479-481.
15. Palivizumab, a humanized Respiratory Syncytial Virus monoclonal antobody, reduces hospitalization from Respiratory Syncytial Virus infection in high risk infants. Pediatrics 1998, 102:531-537. Impact RSV Group.
16. Alvarez R., Elbashir S., Borland T., et al. RNAi-Mediated Silencing of the Respiratory Syncytial Virus Nucleocapsid Defines a Potent Anti-Viral Strategy. Antimicrob Agents Chemother 2009, 53(9):3952-3962.
17. DeVincenzo J.P., Cehelsky J.E., Meyers R., et al. Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against Respiratory Syncytial Virus. Antivir Res 2008, 77:225-231.